Routine CNS screening isn’t yet the standard in early HER2+ breast cancer. Drs. Mouabbi and Birhiray discuss the balance between early detection, clinical benefit, and protecting patients before metastases develop.
Should We Screen for Brain Metastases in HER2+ Disease?
You may also like
Recommended Videos
